Effect of onset age on the levodopa threshold dosage for dyskinesia in Parkinson's disease

Zhijin Zhang,Genliang Liu,Dongxu Wang,Huimin Chen,Dongning Su,Wenyi Kou,Jiajia Zhao,Xuemei Wang,Zhan Wang,Huizi Ma,Tao Feng

DOI: https://doi.org/10.1007/s10072-021-05694-1

2021-12-01

Neurological Sciences

Abstract:IntroductionWith the levodopa threshold effect for dyskinesia observed, threshold dosage of levodopa was identified in the general Parkinson’s disease (PD) population. While early-onset PD (EOPD) and late-onset PD (LOPD) differ in the pathogenesis and clinical manifestations, threshold dosage of levodopa for individualized treatment remains unestablished. The objective of this study was to propose threshold dosage of levodopa in EOPD and LOPD patients, respectively.MethodsData on demographic and clinical and treatment measures were collected in 539 PD patients. Patients were divided into different onset groups using 50 as the cut-off age. We used univariable and multivariable analysis to screen for risk factors for dyskinesia. Receiver operating characteristic curve was used to determine the levodopa threshold dosages for dyskinesia.ResultsThe prevalence of dyskinesia was 47.7% (53/111) in the EOPD group and 24.1% (103/428) in the LOPD group. Risk factors identified for dyskinesia include high levodopa daily dose and levodopa responsiveness for EOPD patients and high levodopa daily dose, long levodopa treatment duration, low body weight, use of entacapone, and high Hoehn–Yahr stage in off state for LOPD patients. The daily levodopa threshold dosages were 400 mg or 5.9 mg/kg for EOPD and 450 mg or 7.2 mg/kg for LOPD.ConclusionEOPD patients had lower levodopa threshold dosage comparing with LOPD patients. Treatment of EOPD requires stricter levodopa dose control to delay the onset of dyskinesia.

neurosciences,clinical neurology